Compare Aurora Cannabis Inc (ACB) vs Axon Enterprise Inc (AXON) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

Axon Enterprise (AXON) trades at $622.20, up 4.21% today, with strong technical momentum as it crosses above key moving averages. The stock shows robust revenue growth, reaching $2.78 billion in 2025, though valuation ratios like a P/E of 250.95 appear elevated. Recent news highlights FAA drone defense approvals and CEO focus on non-lethal public safety technology, driving positive sentiment.

Outlook remains positive with an 80.95% analyst buy rating and $661.50 consensus price target, but risks include high valuation sensitivity and mixed earnings beats. Growth in software services and international expansion offer upside, while cash flow volatility and competitive pressures require monitoring for sustained shareholder value.